Trial Profile
Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous Cell Carcinomas: A Pilot Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms
- Focus Therapeutic Use
- 20 Aug 2021 New trial record